These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Macro- and microadenoma of thyrotropin secreting pituitary tumors--two clinical cases. Hubalewska-Hola A; Fröss K; Kostecka-Matyja M; Sowa-Staszczak A; Szybiński Z; Huszno B; Ptak M Przegl Lek; 2003; 60(11):768-71. PubMed ID: 15058054 [TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics of patients with thyrotropin-secreting pituitary adenoma. Wu YY; Chang HY; Lin JD; Chen KW; Huang YY; Jung SM J Formos Med Assoc; 2003 Mar; 102(3):164-71. PubMed ID: 12783133 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of the long-acting octreotide formulation in patients with thyroid-stimulating hormone-secreting pituitary adenomas after incomplete surgery and octreotide treatment failure. Zhang CF; Liang D; Zhong LY Chin Med J (Engl); 2012 Aug; 125(15):2758-63. PubMed ID: 22931988 [TBL] [Abstract][Full Text] [Related]
26. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. Brucker-Davis F; Oldfield EH; Skarulis MC; Doppman JL; Weintraub BD J Clin Endocrinol Metab; 1999 Feb; 84(2):476-86. PubMed ID: 10022404 [TBL] [Abstract][Full Text] [Related]
27. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186 [TBL] [Abstract][Full Text] [Related]
28. TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide. Fischler MP; Reinhart WH J Endocrinol Invest; 1999 Jan; 22(1):64-5. PubMed ID: 10090139 [TBL] [Abstract][Full Text] [Related]
29. A thyrotropin-secreting pituitary adenoma as a cause of thyrotoxic periodic paralysis. Alings AM; Fliers E; de Herder WW; Hofland LJ; Sluiter HE; Links TP; van der Hoeven JH; Wiersinga WM J Endocrinol Invest; 1998 Nov; 21(10):703-6. PubMed ID: 9854688 [TBL] [Abstract][Full Text] [Related]
30. Thyrotropin-secreting adenoma in an adolescent girl without increased serum thyrotropin-alpha. Korn EA; Gaich G; Brines M; Carpenter TO Horm Res; 1994; 42(3):120-3. PubMed ID: 7527792 [TBL] [Abstract][Full Text] [Related]
31. [Thyroid-stimulating hormone hypophyseal adenoma. A case report]. Gannage MH; Maacaron C; Okais N; Halaby G J Med Liban; 1997; 45(2):97-101. PubMed ID: 9289506 [TBL] [Abstract][Full Text] [Related]
32. Hyperthyroidism due to a pituitary adenoma composed of two different cell types, one secreting alpha-subunit alone and another cosecreting alpha-subunit and thyrotropin. Terzolo M; Orlandi F; Bassetti M; Medri G; Paccotti D; Cortelazzi D; Angeli A; Beck-Peccoz P J Clin Endocrinol Metab; 1991 Feb; 72(2):415-21. PubMed ID: 1704010 [TBL] [Abstract][Full Text] [Related]
34. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337 [TBL] [Abstract][Full Text] [Related]
35. Hyperthyroidism, inappropriate plasma TSH and pituitary adenoma in three patients, two receiving long-term phenothiazine therapy. Dunne FP; Feely MP; Ferriss JB; Keohane C; Murphy D; Perry I Q J Med; 1990 Apr; 75(276):345-54. PubMed ID: 2117296 [TBL] [Abstract][Full Text] [Related]
36. [New elements in the diagnosis and treatment of thyrotropic pituitary adenomas with hyperthyroidism]. Linquette M; Cappoen JP; Mazzuca M Bull Acad Natl Med; 1989 Feb; 173(2):217-20; discussion 221-2. PubMed ID: 2765997 [TBL] [Abstract][Full Text] [Related]
37. [Octreotide in the treatment of thyrotropin-secreting pituitary adenomas]. Podoba J; Hnilica P; Makaiová I; Kovácová S; Rybár M; Gecík K; Belan V; Steno J Vnitr Lek; 1997 Sep; 43(9):607-10. PubMed ID: 9750471 [TBL] [Abstract][Full Text] [Related]
38. TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature. Ness-Abramof R; Ishay A; Harel G; Sylvetzky N; Baron E; Greenman Y; Shimon I Pituitary; 2007; 10(3):307-10. PubMed ID: 17347873 [TBL] [Abstract][Full Text] [Related]
39. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma. Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119 [TBL] [Abstract][Full Text] [Related]
40. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs. Rabbiosi S; Peroni E; Tronconi GM; Chiumello G; Losa M; Weber G Thyroid; 2012 Oct; 22(10):1076-9. PubMed ID: 22947349 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]